Semaglutide News and Research

Latest Semaglutide News and Research

Takeda submits NDA for Alogliptin (SYR-322) in the U.S.

Takeda Pharmaceutical Company Limited (Takeda) has announced that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.

7 Jan 2008

Peptide hormone found in the body prevents obesity and diabetes

A new study finds that a chemical found in the body is capable of promoting weight loss, improving insulin resistance and reversing diabetes in an animal model.

4 Jan 2008

Experimental obesity drug a success for Danish company

An experimental obesity drug manufactured by a Danish company appears to be a success.

20 Nov 2007

Benefit of exenatide has not yet been proven

Since May 2007, a new drug has been available for the treatment of patients with diabetes mellitus type 2 in Germany: exenatide (trade name: Byetta), which is marketed by the manufacturer Eli Lilly.

18 Oct 2007

Incretin-based therapy offers alternative option for treating type 2 diabetes

A review of previous studies indicates that use of a class of medications known as “incretin-based therapy”, which act via certain pathways that affect glucose metabolism may provide modest effectiveness and favorable weight change outcomes for the treatment of type 2 diabetes and may represent an alternative to other hypoglycemic therapies.

11 Jul 2007

Alogliptin for type 2 diabetes shows promise in early trial

Alogliptin, a highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes, demonstrated efficacy in reducing glucose levels throughout the day, in an early phase clinical study.

26 Jun 2007

How and why weight-reducing surgery sometimes cures diabetes

95% of morbidly obese people – those with a Body Mass Index of over 40 – have Type 2 diabetes, sometimes known as maturity-onset diabetes.

5 Jun 2007

Moderate coffee drinking reduces many risks

Although the American Society for Nutrition's popular ,controversy session, at Experimental Biology 2007 focuses on the health effects of coffee drinking, panel chair Dr. James Coughlin, a toxicology/safety consultant at Coughlin & Associates, says that recent advances in epidemiologic and experimental knowledge have transformed many of the negative health myths about coffee drinking into validated health benefits.

1 May 2007

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Intarcia Therapeutics has announced final results from a Phase 2 study of omega interferon with or without ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

15 Apr 2007

Natural fibre may help overweight achieve a healthy body weight

It sounds almost too good to be true, but Dr. Raylene Reimer, a researcher at the University of Calgary, Faculty of Kinesiology, believes she may have found an important weapon in the war against obesity.

31 Jan 2007

Melanin concentrating hormone found to be involved with insulin production

A new Joslin Diabetes Center-led study has shown conclusively that a neuropeptide, melanin concentrating hormone (MCH), found in the brain and known for its role in increasing appetite in people, plays a role in the growth of insulin-producing beta cells and the secretion of insulin.

28 Jan 2007

Pine nut oil boosts appetite suppressors

In the face of the growing obesity health challenge, "appetite suppressants are increasingly interesting because they work on the very simple premise of 'What you don't eat now, you won't need to lose later,'" Alexandra Einerhand, director, nutrition and toxicology-Europe at Lipid Nutrition notes.

4 Apr 2006

FDA affirms safety of Aspartame

The Calorie Control Council has stated that a rat study conducted by Italy's Ramazzini Institute is totally contradictory to the extensive scientific research and regulatory reviews conducted on aspartame. The U.S. Food & Drug Administration (FDA) has said they are not recommending any changes in the use of aspartame.

13 Feb 2006

Severe hypoglycemia - complication of gastric bypass surgery

Physicians monitoring patients who have undergone gastric bypass surgery should be on the alert for a new, potentially dangerous hypoglycemia (low blood glucose) complication that, while rare, may require quick treatment, according to a new study

12 Oct 2005

Myriad Genetics nears completion of antithrombin drug trial

Myriad Genetics announced today that it is rapidly nearing completion of the preclinical data package on MPC-0920, its antithrombin drug candidate, for submission to the FDA prior to beginning human clinical trials.

11 Oct 2005

Genelabs drug discovery team advances compounds against the hepatitis C virus

Genelabs Technologies today announced that a non-nucleoside compound from its internal Hepatitis C virus (HCV) drug discovery program has advanced into preclinical development.

4 Aug 2005

World first air purification technology for H5N1 Avian Influenza

Sharp Corporation has demonstrated that Plasmacluster Ions reduce activity of the highly fatal and highly pathogenic airborne H5N1 avian influenza ("bird flu") virus by 99%.

6 Jun 2005

Incretin hormones, a new wave of promising diabetes research

A new understanding of specialized incretin (or gut) hormones may lead to significant advances in the treatment and management of type 2 diabetes. This conclusion and other recent research were reported recently at the 14th Annual Meeting and Clinical Congress of the American Association for Clinical Endocrinologists (AACE) in Washington, DC.

23 May 2005

Human Genome Sciences announces agreement with GSK for development of drug to treat diabetes

Human Genome Sciences today announced an agreement with GlaxoSmithKline under which GlaxoSmithKline has acquired exclusive worldwide rights to develop and commercialize Albugon (albumin-glucagon-like peptide-1, GLP-1), a drug currently in late-stage preclinical development by Human Genome Sciences for potential use in the treatment of diabetes.

26 Oct 2004

New drug application for exenatide has been accepted for review

Amylin Pharmaceuticals and Eli Lilly today announced that the New Drug Application for exenatide has been accepted for review by the Food and Drug Administration.

2 Sep 2004